
Vaxcyte, Inc.
NASDAQ:PCVX
73.02 (USD) • At close March 13, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|---|
Omzet
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Kosten van de omzet
| 0 | 75 | 9.196 | 1.8 | 1.405 | 1.232 | 1.037 | 0 |
Brutowinst
| 0 | -75 | -9.196 | -1.8 | -1.405 | -1.232 | -1.037 | 0 |
Brutowinstmarge
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Onderzoek- en ontwikkelingskosten
| 476.644 | 332.341 | 169.451 | 78.411 | 73.564 | 45.607 | 30.145 | 12.785 |
Algemene en administratieve kosten
| 92.902 | 60.7 | 39.81 | 25.259 | 16.017 | 8.546 | 5.388 | 5.048 |
Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Verkoop-, algemene en administratieve kosten
| 92.902 | 60.7 | 39.81 | 25.259 | 16.017 | 8.546 | 5.388 | 5.048 |
Overige kosten
| 0 | 0 | -1.931 | -1.585 | -2.478 | -0.237 | 5.178 | 0 |
Bedrijfskosten
| 569.546 | 468.041 | 207.33 | 102.085 | 87.103 | 53.916 | 35.533 | 17.402 |
Bedrijfsresultaat
| -569.546 | -468.041 | -232.256 | -103.67 | -89.581 | -54.153 | -35.533 | -17.833 |
Bedrijfsresultaat ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Totaal overige inkomsten en kosten netto
| 105.619 | 65.775 | 8.771 | 3.593 | 0.364 | 3.879 | 6.048 | 0.595 |
Inkomen voor belasting
| -463.927 | -402.266 | -223.485 | -100.077 | -89.217 | -50.274 | -29.485 | -17.238 |
Inkomen voor belasting ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Belastingkosten
| 0 | 0 | 16.155 | 0.007 | -1.398 | 3.225 | 6.123 | 0 |
Nettowinst
| -463.927 | -402.266 | -239.64 | -100.084 | -87.819 | -53.499 | -29.485 | -17.238 |
Nettowinstmarge
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WPA (Winst Per Aandeel)
| -3.8 | -4.14 | -3.69 | -1.93 | -2.97 | -14.1 | -8.12 | -4.84 |
Verwaterde WPA
| -3.8 | -4.14 | -3.69 | -1.93 | -2.97 | -14.1 | -8.12 | -4.83 |
EBITDA
| -569.546 | -464.885 | -214.289 | -98.277 | -87.805 | -49.002 | -28.373 | -17.208 |
EBITDA ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |